Time to progression of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Recurrence of liver metastases Number of participants developing recurrences of liver metastases · people with liver metastases
The intervention showed no clear difference in recurrence of liver metastases Number of participants developing… (low certainty).
1 finding from 1 review
Intervention not reported
Time to progression of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Sulfamethoxazole + trimethoprim (1 RCT, 60 participants) · people with liver cirrhosis
The intervention may leads to lower sulfamethoxazole + trimethoprim (1 RCT, 60 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Sulfamethoxazole + trimethoprim (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes sulfamethoxazole + trimethoprim (no direct RCT) (very low certainty).
1 finding from 1 review
HR 2.62 [0.62, 11.91]
Studies not reported
Very low
Intervention not reported
Sulfamethoxazole +trimethoprim (1 RCT, 60 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes sulfamethoxazole +trimethoprim (1 RCT, 60 participants) (very low certainty).
1 finding from 1 review
HR 0.47 [0.2, 1]
Studies not reported
Very low
All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether methionine and supportive treatment changes mortality compared with supportive treatment (very low certainty).
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
Methionine and supportive treatment may leads to lower hepatotoxicity compared with supportive treatment (low certainty).
1 finding from 1 review
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether methotrexate plus ursodeoxycholic acid (UDCA) changes mortality at maximal compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vomiting, retching, or antiemetics from 0‐2 hours · people with paracetamol (acetaminophen) overdose
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics from 0‐2 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
1 finding from 1 review
Vomiting, retching, or antiemetics 0‐12 hours · people with paracetamol (acetaminophen) overdose
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics 0‐12 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
1 finding from 1 review
Anthropometric measurements: mid‐arm circumference (cm) · people with Child‐Pugh stage A or B cirrhosis
1 finding from 1 review
Anthropometric measurements: mid‐thigh circumference (cm) · people with Child‐Pugh stage A or B cirrhosis
1 finding from 1 review
Hepatic encephalopathy · people with hepatic encephalopathy
Branched‐chain amino acids (BCAA) leads to lower hepatic encephalopathy Psychometric and clinical assessments compared with control (high certainty).
1 finding from 1 review
Cosmesis · people undergoing laparoscopic cholecystectomy.
1 finding from 1 review
All‐cause mortality at last · people with liver metastases
It is very uncertain whether percutaneous ethanol injection changes mortality at last compared with no intervention, other ablation methods, or systemic treatment (very low certainty).
1 finding from 1 review
Time to mortality · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found